VistaGen Wins NIH Funding

South San Francisco-based VistaGen Therapeutics, Inc., a biopharmaceutical firm specializing in the use of embryonic stem cell technologies in drug development, was awarded a $1.2 million grant from National Institutes of Health, the company announced Tuesday.

The funding is the final phrase of a $4.3 grant for the development of AV-101, a potential treatment for neuropathic pain, Parkinson’s disease and epilepsy.

Bay Area pot shops face mob robberies — get little help

‘It’s proving to be unbearable for cannabis operators’

By Veronica Irwin
Supes vs. Mayor: Fight breaks out on how to spend Prop I money

Board approves $64 million to acquire small apartment buildings against Breed’s wishes

By Benjamin Schneider
Letterform Archive reopens with major Bauhaus exhibition

Revolutionary art school’s legacy: To show design is the world we live in

By Max Blue Special to The Examiner